CO6541545A2 - Compuestos de espiropiperidina como antagonistas del receptor orl-1 - Google Patents

Compuestos de espiropiperidina como antagonistas del receptor orl-1

Info

Publication number
CO6541545A2
CO6541545A2 CO12073055A CO12073055A CO6541545A2 CO 6541545 A2 CO6541545 A2 CO 6541545A2 CO 12073055 A CO12073055 A CO 12073055A CO 12073055 A CO12073055 A CO 12073055A CO 6541545 A2 CO6541545 A2 CO 6541545A2
Authority
CO
Colombia
Prior art keywords
orl
compounds
spyropiperidine
antrogonists
receiver
Prior art date
Application number
CO12073055A
Other languages
English (en)
Inventor
Collado Ana Belen Benito
Buezo Nuria Diaz
Escribano Miguel Angel Toledo
Concepcion Pedregal-Tercero
Grau Maria Angeles Martinez
Blanco Celia Lafuente
Aguado Alma Maria Jimenz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6541545A2 publication Critical patent/CO6541545A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos derivados de espiropiperidina de la fórmula:Así corno a sus métodos de obtención, y composiciones farmacéuticas donde puedan estar presentes actuando como antagonistas del receptor ORL-1, las cuales tienen aplicación en el tratamiento de enfermedades mediadas por la actividad de dicho receptor, tales como: depresión, migraña y/o obesidad.
CO12073055A 2009-11-16 2012-05-04 Compuestos de espiropiperidina como antagonistas del receptor orl-1 CO6541545A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
CO6541545A2 true CO6541545A2 (es) 2012-10-16

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12073055A CO6541545A2 (es) 2009-11-16 2012-05-04 Compuestos de espiropiperidina como antagonistas del receptor orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (es)
EP (1) EP2501703B1 (es)
JP (1) JP5680101B2 (es)
KR (1) KR101363830B1 (es)
CN (1) CN102612520B (es)
AR (1) AR078863A1 (es)
AU (1) AU2010319581C1 (es)
CA (1) CA2796161C (es)
CO (1) CO6541545A2 (es)
CR (1) CR20130087A (es)
DK (1) DK2501703T3 (es)
DO (1) DOP2012000135A (es)
EA (1) EA020848B1 (es)
EC (1) ECSP12011902A (es)
ES (1) ES2435814T3 (es)
HK (1) HK1169988A1 (es)
HN (1) HN2012001011A (es)
HR (1) HRP20130967T1 (es)
IL (1) IL219370A (es)
JO (1) JO2887B1 (es)
MA (1) MA33751B1 (es)
ME (1) ME01537B (es)
MX (1) MX2012005691A (es)
MY (1) MY160665A (es)
NZ (1) NZ600006A (es)
PE (1) PE20121430A1 (es)
PL (1) PL2501703T3 (es)
PT (1) PT2501703E (es)
RS (1) RS53018B (es)
SI (1) SI2501703T1 (es)
TW (1) TWI465453B (es)
UA (1) UA107943C2 (es)
WO (1) WO2011060035A1 (es)
ZA (1) ZA201202967B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731621A (en) 2009-12-04 2019-01-25 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
NZ746490A (en) 2012-10-02 2018-12-21 Bayer Cropscience Ag Heterocyclic compounds as pesticides
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環(4.5)癸烷衍生物
AR105821A1 (es) 2015-09-09 2017-11-15 Lilly Co Eli COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
IL264446B1 (en) 2016-07-29 2024-05-01 Pgi Drug Discovery Llc Compounds and compositions and their use
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
US11008336B2 (en) 2017-03-02 2021-05-18 Eli Lilly And Company Compounds useful for inhibiting RORγt
SI3589637T1 (sl) * 2017-03-02 2021-08-31 Eli Lilly And Company Spojine uporabne pri inhibiciji ROR-GAMMA-T
EP3661929B1 (en) 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
WO2019161238A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US11738002B2 (en) 2020-04-14 2023-08-29 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders
EP4204423A1 (en) 2020-08-26 2023-07-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
WO2023154344A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
DE60033071T2 (de) 1999-12-06 2007-08-23 Euro-Celtique S.A. Triazospiroverbindungen mit nociceptin-rezeptoraffinität
AU2002311833B2 (en) 2001-04-18 2005-04-28 Euro-Celtique S.A. Spiropyrazole compounds
WO2002088089A1 (fr) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
EP1420020B1 (en) 2001-07-23 2008-05-28 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivative
CA2466915A1 (en) * 2002-01-28 2003-08-07 Pfizer Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
AU2003235912A1 (en) 2002-05-10 2003-11-11 Taisho Pharmaceutical Co., Ltd. Spiro-ring compound
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
PL377047A1 (pl) 2002-09-09 2006-01-23 Janssen Pharmaceutica, N.V. Hydroksyalkilopodstawione pochodne 1,3,8-triazaspiro [4,5]-dekan-4-onu przydatne w leczeniu zaburzeń, w których pośredniczy receptor ORL-1
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US7354925B2 (en) * 2004-03-29 2008-04-08 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
MX2010009955A (es) 2008-03-27 2010-09-30 Gruenenthal Gmbh Derivados de ciclohexano espirociclicos sustituidos.

Also Published As

Publication number Publication date
CA2796161A1 (en) 2011-05-19
US20110118251A1 (en) 2011-05-19
TW201127841A (en) 2011-08-16
PE20121430A1 (es) 2012-10-26
AU2010319581A1 (en) 2012-06-07
HRP20130967T1 (hr) 2013-11-22
NZ600006A (en) 2014-05-30
KR20130026523A (ko) 2013-03-13
MX2012005691A (es) 2012-06-13
AR078863A1 (es) 2011-12-07
HK1169988A1 (en) 2013-02-15
CR20130087A (es) 2013-04-17
ES2435814T3 (es) 2013-12-23
MA33751B1 (fr) 2012-11-01
ECSP12011902A (es) 2012-07-31
EP2501703B1 (en) 2013-09-18
CA2796161C (en) 2015-03-17
JP2013510859A (ja) 2013-03-28
WO2011060035A1 (en) 2011-05-19
EP2501703A1 (en) 2012-09-26
UA107943C2 (en) 2015-03-10
JP5680101B2 (ja) 2015-03-04
EA201290352A1 (ru) 2012-10-30
RS53018B (en) 2014-04-30
IL219370A (en) 2015-01-29
AU2010319581B2 (en) 2013-12-19
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25
PL2501703T3 (pl) 2014-02-28
ME01537B (me) 2014-04-20
JO2887B1 (en) 2015-03-15
DOP2012000135A (es) 2012-08-15
DK2501703T3 (da) 2013-10-14
US8232289B2 (en) 2012-07-31
IL219370A0 (en) 2012-06-28
KR101363830B1 (ko) 2014-02-14
EA020848B1 (ru) 2015-02-27
SI2501703T1 (sl) 2013-11-29
AU2010319581C1 (en) 2014-05-15
PT2501703E (pt) 2013-11-26
MY160665A (en) 2017-03-15
CN102612520A (zh) 2012-07-25
CN102612520B (zh) 2015-04-08
HN2012001011A (es) 2015-08-31

Similar Documents

Publication Publication Date Title
CO6541545A2 (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
NI201300043A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
GT200900231A (es) Moduladores 2-aminopirimidina del receptor de histamina h4
PH12015501289B1 (en) Novel benzimidazole derivatives as ep4 antagonists
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
CR11751A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta3
EA201290296A1 (ru) Циклические пептиды, специфичные к рецептору меланокортина-1
CR20110509A (es) Composicion farmaceutica
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
BR112012007747B8 (pt) compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
DK3061821T3 (da) Sammensætninger til behandling af forstyrrelser lindret af muskarinreceptoraktivering
UY32574A (es) Antagonistas del receptor cxcr3
CO6781501A2 (es) Dihidrofuranos condensados en calidad de modulares de gpr119 para el tratamiento de diabetes, obesidad y trastornos relacionados
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
EA201391618A1 (ru) Комбинация, содержащая умеклидиний и кортикостероид
CL2013002412A1 (es) Compuestos derivados de (piperidin-4-il)-ureas; composicion farmaceutica; y uso como antagonistas del receptor grelina en el tratamiento de la obesidad, trastornos alimenticios, diabetes, caquexia causada por el cancer, insuficiencia cardiaca congestiva, entre otras.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
CR11600A (es) Derivados de indazol
UY31840A (es) Pirrolidin amidas sustituidas como moduladores del receptor histamina h3
SV2011003784A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
UY32410A (es) Azetidinas como antagonistas del receptor de histamina3

Legal Events

Date Code Title Description
FG Application granted